Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors

Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failu...

Full description

Saved in:
Bibliographic Details
Published in:Mol Oncol
Main Authors: Rye, Inga H., Trinh, Anne, Sætersdal, Anna B., Nebdal, Daniel, Lingjærde, Ole Christian, Almendro, Vanessa, Polyak, Kornelia, Børresen‐Dale, Anne‐Lise, Helland, Åslaug, Markowetz, Florian, Russnes, Hege G.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2018
Subjects:
Research Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6210052/
https://ncbi.nlm.nih.gov/pubmed/30133130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12375
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items